Search clinical trials for: PD-1 Blockade

Total 14832 results

Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Tongji Hospital; Hunan Cancer... and other collaborators

Recruiting

Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy

Nasopharyngeal Carcinoma | De-escalation Therapy

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Carotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid Artery

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Sun Yat-sen University
Bristol-Myers Squibb

Active, not recruiting

Concurrent and Adjuvant PD-1 Blockade Combined With Induction Chemotherapy Plus Radiotherapy in Nasopharyngeal Carcinoma (PLATINUM)

Nasopharyngeal Carcinoma

China
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma (DIAMOND)

Nasopharyngeal Carcinoma

China
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS) (BLESS)

Esophageal Cancer

China
University of Colorado, Denver
National Cancer Institute (NCI); Cancer League of Colorado

Withdrawn

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Colorectal Cancer | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Sinocelltech Ltd.

Unknown

Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Tongji University

Recruiting

A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NSCLC, Stage IIIA | EGF-R Negative Non-Small Cell Lung Cancer | ALK Negative NSCLC

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients

Non-Small Cell Lung Cancer

Mexico
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Capital Medical University
Duke University

Completed

Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors

Neoplasms

China
Capital Medical University
Duke University; Geneplus-Beijing Co. Ltd.

Completed

Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

Neoplasms | Lung Cancer

China
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Zhongnan Hospital

Recruiting

Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival

China
Beijing Friendship Hospital

Recruiting

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Esophageal Carcinoma | Neoadjuvant Immunotherapy

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
CureVac
Syneos Health; Cromos Pharma LLC

Active, not recruiting

Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC

Carcinoma, Adenoid Cystic | Melanoma (Skin) | Squamous Cell Carcinoma of the Skin | Carcinoma, Squamous Cell of Head and Neck

Spain, France, Austria, Germany, Russian Federation
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Adanate, Inc

Recruiting

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

United States
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Yonsei University

Completed

Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy

General Anesthesia

Korea, Republic of
The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
Waterstone Hanxbio Pty Ltd

Completed

The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

Advanced Solid Tumor

Australia
Second Affiliated Hospital, School of Medicine,...
Westlake Therapeutics

Recruiting

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

Advanced Lung Cancer

China
Cancer Hospital of Guangxi Medical University

Recruiting

Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Sintilimab

China
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Nationwide Children's Hospital

Terminated

Frequency of Residual Neuromuscular Blockade in the Pediatric Population

Neuromuscular Blockade

United States
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Agenus Inc.

Completed

Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Cervical Cancer | Advanced Cancer

France, United States, Belgium, Australia, Spain, Estonia, Brazil, Chile, Poland
Peking University First Hospital
YiZhou International Cancer Hospital

Unknown

Combination of Hypofractionated Proton Therapy With Immunotherapy (I-HypoPT)

Immunotherapy | Proton Therapy
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Kyung Hee University Hospital at Gangdong
Merck Sharp & Dohme LLC

Completed

Intraoperative Neuromuscular Blockade and Postoperative Atelectasis

Thoracic Surgery | One-lung Ventilation

Korea, Republic of
Harbin Medical University

Unknown

Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure

Chronic Heart Failure

China
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Beijing Tongren Hospital

Not yet recruiting

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Extranodal NK/T-cell Lymphoma, Nasal Type

Search clinical trials for: PD-1 Blockade

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations